Effect of Liraglutide, a Glucagon-Like Peptide-1 Analogue, on Left Ventricular Function in Stable Chronic Heart Failure Patients with and Without Diabetes (LIVE)—a Multicentre, Double-Blind, Randomised, Placebo-Controlled Trial
European Journal of Heart Failure2016Vol. 19(1), pp. 69–77
Citations Over TimeTop 1% of 2016 papers
Anders Jorsal, Caroline Kistorp, Pernille Holmager, Rasmus Stilling Tougaard, Roni Nielsen, Anja Hänselmann, Brian Nilsson, Jacob Eifer Møller, Jakob Hjort, Jon Rasmussen, Trine Welløv Boesgaard, Morten Schou, Lars Videbæk, Finn Gustafsson, Allan Flyvbjerg, Henrik Wiggers, Lise Tarnow
Abstract
Liraglutide did not affect left ventricular systolic function compared with placebo in stable chronic heart failure patients with and without diabetes. Treatment with liraglutide was associated with an increase in heart rate and more serious cardiac adverse events, and this raises some concern with respect to the use of liraglutide in patients with chronic heart failure and reduced left ventricular function. More data on the safety of liraglutide in different subgroups of heart failure patients are needed.
Related Papers
- → Effects of the Long-Acting Human Glucagon-Like Peptide-1 Analog Liraglutide on β-Cell Function in Normal Living Conditions(2007)83 cited
- Liraglutide: A human GLP-1 analogue for the treatment of type 2 diabetes(2009)
- → PM426. Effect of a glucagon-like peptide 1 (GLP-1) receptor agonist, liraglutide, on cognition and body weight during antipsychotic treatment(2016)
- → Human glucagon-like peptide-1 analogue-Liraglutide(2008)
- → Hot off the press: Insight to the cardioprotective effects of GLP-1 (glucagon-like peptide-1) analog liraglutide(2022)